Gordon, Kenneth B.
Blauvelt, Andrew
Bachelez, Hervé
Coates, Laura C.
Van den Bosch, Filip E.
Kaplan, Blair
Koetse, Willem
Ashley, Doug G.
Lippe, Ralph
Sinvhal, Ranjeeta
Papp, Kim A.
Funding for this research was provided by:
AbbVie
Article History
Received: 14 June 2024
Accepted: 10 July 2024
First Online: 17 August 2024
Declarations
:
: The protocols for all the studies included in this analysis were approved by the Institutional Review Board or ethics committee at each participating site. All studies were conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines and the ethical principles of the Declaration of Helsinki. All enrolled patients provided written informed consent before undergoing study-related procedures.
: Kenneth B Gordon has received honoraria for serving as a consultant and/or grants as an investigator from AbbVie, Almirall, Amgen, Boehringer Ingelheim, BMS, Celgene, Dermira, GSK, Janssen, Leo, Lilly, Novartis, Pfizer, Regeneron, Sanofi-Aventis, Sun and UCB. Andrew Blauvelt has served as a speaker (received honoraria) for Eli Lilly and Company and UCB; has served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Celldex, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome and Xencor; has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma and Ventyx; and owns stock in Lipidio and Oruka. Hervé Bachelez has received honoraria or fees for serving on advisory boards, as a speaker and as a consultant and grants as an investigator from AbbVie, Almirall, Amgen, Bayer, Baxalta, Biocad, BI, Celgene, Dermavant, Janssen, Lilly, Leo, Menarini, MSD, Novartis, Pfizer, Pierre Fabre, Sandoz, Sun and UCB. Laura C Coates has received grants/research support from AbbVie, Amgen, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB; has worked as a paid consultant for AbbVie, Amgen, BI, BMS, Celgene, Gilead, Galapagos, Janssen, Lilly, Moonlake, Novartis, Pfizer and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Galapagos, Gilead, GSK, Janssen, Lilly, Medac, Novartis, Pfizer and UCB. Filip E Van den Bosch received consulting and/or speaker fees from AbbVie, BMS, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer and UCB. Blair Kaplan, Willem Koetse, Doug G Ashley, Ralph Lippe and Ranjeeta Sinvhal are full-time employees of AbbVie and may own stock/stock options. Kim A Papp is a consultant and/or Speaker, and/or Investigator, and/or Scientific Officer, and/or Steering Committee Member and/or Advisory Board Member for AbbVie, Acelyrin, Akros, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, Dice Pharmaceuticals, Alumis, Eli Lilly, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, Leo Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus, Novartis, Pfizer, Reistone, Sanofi-Aventis/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB and Zai Lab Co.